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Abstract The introduction of oxaliplatin as adjuvant
treatment for stage III colon cancer in 2004 has been
the last practice changing progress in adjuvant treat-
ment for patients with early colon cancer. Since then,
many prognostic and predictive biomarkers have been
studied, but only DNA mismatch repair status has been
validated as having an important prognostic value.
Accordingly, TNM and clinical-pathological patterns,
such as pT4 lesions and lymph node sampling <12
nodes, are the main factors that guide physicians’
choice regarding adjuvant treatment. More recently,
many biomarkers showed promising results: POLE,
ErbB2, CDX2, SMAD4, BRAF and KRAS. In addition
to these, immune-contexture, molecular classification,
and gene signatures could become new ways to better
classify colon cancer patients with more discriminatory
power than TNM. The aim of this review is to report
the state-of-the-art of prognostic and predictive factors
in the adjuvant setting and which of these could
modify clinical practice and maybe replace TNM
classification.
Key Points
No  significant  development in treatment strategies  for
colon cancer patients in the  adjuvant setting has been
made in the last decade.
Many predictive and prognostic biomarkers showed
promising results to better determine patients’ prognosis
and treatment response.
Further studies are needed since these biomarkers can 
change our clinical practice.
1 Introduction
Colorectal cancer (CRC) is a major cause of death globally,
with an estimated 134,490 new cases and 49,190 deaths oc-
curring in 2016 in the USA [1]. In 75% of cases the tumour is
diagnosed when it is still in an early stage and surgery alone is
potentially curative [2]. The role of adjuvant therapy has been
well established for stage III colon cancer (CC) since 2004,
when Thierry André and colleagues [3] demonstrated the ben-
efit of fluoropyrimidine plus oxaliplatin in terms of disease-
free survival (DFS) and overall survival (OS) [4, 5]. Much
more controversial is the use of adjuvant therapy in stage II
CC, in which the absolute benefit of single-agent 5-fluoroura-
cil (5-FU) ranges from 2% to 5% [6]. Although the TNM stage
system and the American Joint Committee on Cancer/Union
for International Cancer Control (AJCC/UICC) system are the
main prognostic factors used in clinical practice, extensive
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intra-stage variability in outcome is well known, probably
reflecting the heterogeneity of this disease. To develop more
effective therapies, it is critical to identify prognostic and pre-
dictive markers of recurrence and identify novel targets of
therapy for the patients who are potentially curable. Our re-
view focuses on well-known prognostic factors and on those
that could potentially modify clinical practice in the future.
2 Histopathological and Clinical Features
In stage III CC the standard of care is fluoropyrimide- and
oxaliplatin-based chemotherapy, after surgical intervention.
Adjuvant treatment should be administered as soon as the
patient is medically able, but not later than 6–8 weeks after
resection [7, 8]. The exact duration for this therapy is 6 months
of FOLFOX (5FU, folinic acid and oxaliplatin) or XELOX
(capecitabine and oxaliplatin), but results from completed tri-
als aimed to demonstrate the non-inferiority of three months
of chemotherapy vs the standard 6 months, are expected in a
few months. A shorter duration of therapy, if equally effica-
cious, would be advantageous for patients and Health Care
Systems. Therefore, the results from TOSCA trial [9], that is
the first trial comparing 3 versus 6 months of adjuvant che-
motherapy completing accrual within the international initia-
tive of treatment duration evaluation (International Duration
Evaluation of Adjuvant, IDEA) [10], are very crucial because
they will profoundly impact clinical practice.
In this setting, the benefit of 5-FU in terms of reducing the
risk of relapse is around 15% [11], plus the benefit of
oxaliplatin that ranges in 4–6% [3–5]. Although almost 50%
of patients are cured by surgery alone, we do not have any
biomarkers available to select those patients who do not need
chemotherapy and to prevent them from the exposure of che-
motherapy toxicity.
In stage II, for low-risk patients the benefit derived from
5-FU adjuvant chemotherapy is very low. Only patients de-
fined as at high-risk for relapse are considered for adjuvant
treatment. The histopathological and clinical features to define
a patient as high risk are: pT4 lesions, lymphovascular or
perineural invasion, tumour presentation with perforation or
obstruction, poorly differentiated histology, or lymph node
sampling <12 nodes. In these patients, the use of oxaliplatin
has no benefit and 5-FU or capecitabine are recommended [6].
3 Prognostic Biomarkers for Stage II and III CC
Researchers and clinicians need prognostic biomarker to de-
cide when to treat and predictive biomarkers to decide which
agents to use to treat patients. Unfortunately, there are no
predictive biomarkers validated for neither stage II nor III
CC, although much effort was invested and potential candi-
dates have been identified.
3.1 CDX2
The role of Caudal-type homeobox transcription factor 2
(CDX2) as a prognostic biomarker and its association with
advanced stage, CpG island methylator phenotype-high
(CIMP-high), and high tumour grade has been widely demon-
strated in the past [12–14]. More recently, its expression has
been evaluated in 2115 tumour samples by Dalerba and col-
leagues [15] (Table 1). The results revealed that without adju-
vant chemotherapy, CDX2-negative tumours (only 5% of all
patients) were associated with a lower rate of disease-free
survival than CDX2-positive tumours. In addition, patients
with stage II or stage III CDX2-negative CC might benefit
from adjuvant chemotherapy and adjuvant chemotherapy
might be a treatment option for patients with stage II CDX2-
negative disease, who are commonly treated with surgery
alone. These findings need to be further confirmed, ideally
within the framework of prospective and randomized clinical
trials.
3.2 MSI
Deficient DNA mismatch repair (dMMR) status is found in
about 15% of CRCs. In fact, its prevalence is higher in early
stage and decreased in advanced disease (20% in stage I-II,
12% in stage III and 4% in stage IV). The dMMR can be
investigated by testing for loss of an MMR protein
(immunohistochemistry) or forMSI using a PCR-based assay:
MSI-high (MSI-H) tumours display loss of at least one MMR
protein with immunohistochemistry (MLH1, MSH2, MSH6,
and PMS2) or instability in two or more of the five microsat-
ellite markers (BAT25, BAT26, D2S123, D5S346, and
D17S250) with a PCR-based assay [30]. The dMMR status
is one of the most studied and well-established positive prog-
nostic factor, especially in early-stages of CC. In all the stud-
ies, microsatellite instability (MSI) has been associated with a
better outcome in comparison of microsatellite stability
(MSS), in terms of time to recurrence (TTR), relapse free
survival (RFS) and OS [16–19, 31]. However, the prognostic
role in stage III CC is less robust than in stage II. Moreover, in
an important study by Sinicrope and colleagues [20] the au-
thors noticed a possible connection between microsatellite
status and the localization of primary tumour, with a positive
prognostic factor only for right-sided tumours.
Probably because of the good prognosis for patients with
stage IIMSI-HCC, no evidence of benefit with adjuvant 5-FU
has been found [32–34], and for patients with stage II MSI-H,
adjuvant chemotherapy is not recommended.
In the future, potential treatment options for patients with
MSI-H CC may include immune checkpoint inhibitors. The
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use of immune checkpoint inhibitors has revolutionized the
treatment of some types of cancer, especially non-small cell
lung cancer (NSCLC), melanoma, renal cancer, and head and
neck and bladder. It has been recently demonstrated that
MSI-H tumours have an increased mutational burden that
could be responsible for the generation of neoepitopes, even-
tually recognizable by the immune system [35]. Indeed, nu-
merous studies have demonstrated that MSI-H tumours are
highly infiltrated with T cells, including cytotoxic T lympho-
cytes - CTLs [36–41], a well-established good prognostic fac-
tor. Furthermore, Le and colleagues have recently demonstrat-
ed the MSI status as a predictive marker for response to pro-
grammed death 1 (PD-1) blockade in patients with stage IV
CRC [36], opening new therapeutic options for these patients
even into first line treatment.
3.3 BRAF
In sporadic CRCs, BRAF mutation is seen in approximately
60% of MSI-H tumours and only in 5–10% of microsatellite
stable (MSS) tumours [42]. BRAF V600E mutations are as-
sociated with several clinicopathological parameters, and the
ones most often reported are: proximal location, higher age,
female gender, MSI-H, high grade, and mucinous histology.
The BRAF V600E mutation has been widely investigated,
and its negative prognostic impact on stage II and III CC has
been observed in numerous studies [17, 19–23, 31, 43–45].
BRAF mutation has the greatest impact in terms of OS, espe-
cially for left-sided and MSS tumours. The strong association
between MSI-H and BRAF mutation makes it harder to dis-
tinguish the role of the distinct factors in prognosis. However,
in a retrospective analysis of the PETACC-3 trial [21] there
was no evidence for prognostic value in MSI or right-sided
tumour groups. Nevertheless, in three different studies no
prognostic role of BRAF mutations has been demonstrated
[46–48]. To underline the strong correlations between these
useful biomarkers, it has been recently demonstrated that in
MSI-H tumours the concomitant evaluation of both BRAF
and KRAS provides useful prognostic information beyond
the evaluation of either variable separately. Most importantly,
patients with double wild-type (dWT) cancers had a highly
favourable survival with 5-year cancer-specific survival (CSS)
of 93% (95% CI 84–100%) compared to patients with either
BRAF or KRAS mutated cancers (5-year CSS 76%, 95% CI
67–85%), especially in stage II patients with dWT cancers in
whom no cancer-specific deaths were observed [49].
3.4 KRAS
Different important studies examined the prognostic impact of
specific KRAS mutations in CC, considering BRAF muta-
tional status as a confounding variable. The presence of
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confers a worse prognosis, with reduced DFS and OS [24–26,
50] in resected tumours. In fact, the importance and the impact
of KRAS mutation on prognosis is still debated and not clear,
since the large PETACC-3 translational study [31] and data
from the National Surgical Adjuvant Breast and Bowel
Project (NSABP) clinical trials C-07 (n = 1836) and C-08
(n = 463) [19] reported no prognostic value in terms of OS,
RFS, and TTR [51]. Mutation of KRAS occurs in 40% of
sporadic CRCs, and it is an established predictor of absence
of response to epidermal growth factor receptor (EGFR)–
targeted agents in the metastatic setting [52], but in the adju-
vant setting targeting this pathway failed to improve DFS and
OS in both PETACC-8 and NO147 trials [53, 54].
Furthermore, no definitive results exist concerning the predic-
tive role of KRAS with FU/FA chemotherapy [17]. More re-
cently, J. Taieb and colleagues presented results from the
PETACC-8 trial (cetuximab + FOLFOX vs FOLFOX) in full
WT patients (RAS & BRAF). Although cetuximab did not
significantly improve TTR, DFS, or OS in patients with
RAS WT or RAS & BRAF dWT tumours (HR ranging from
0.77 to 1.05, all p > 0.05), the curves clearly separated after 2–
3 years and stayed so at 5-year follow-up, encouraging inves-
tigation of these important results in a prospective analysis
[55].
3.5 ErbB2
Following the MOSAIC trial, no advances have been made in
the adjuvant treatment setting. ErbB2 amplification has been
recently shown as a potential targetable alteration inmetastatic
CRC in the HERACLES trial [56]. In this proof-of-concept,
multicentre, open-label, phase 2 trial, 27 patients with HER2-
positive metastatic CRC (mCRC), refractory to standard ther-
apy were enrolled. The patients received dual-targeted therapy
with trastuzumab and lapatinib, showing a disease control rate
of 78%, with 34% partial responses (PR) or complete re-
sponses (CR). This discovery reinforces the interest in study-
ing the occurrence and the prognostic role of ErbB2 alter-
ations in stage III CC where we need to improve adjuvant
strategies. Recently, P. Laurent-Puig and colleagues showed
the poor prognostic impact of ErbB2 alterations (mutations in
1% or amplification in 3%) in about 1800 tumour samples
from the PETACC8 trial [27]. Altogether, ErbB2 alterations
were present in 64 patients (3.8%). In a univariate analysis,
ERBB2 alterations were associated with shorter time to recur-
rence (HR: 1.55 [95%CI: 1.02; 2.36] p = 0.04) and shorter
overall survival (HR: 1.57 [0.99; 2.5] p = 0.05). This prog-
nostic value was maintained after adjustment for treatment,
RAS mutation, histological grade, tumour location, pT and
pN status, bowel obstruction or perforation, and venous or
lymphatic embolism. In conclusion, its poor prognostic value
supports the testing of anti-ErbB2 therapies in the adjuvant
setting in investigational trials.
3.6 POL-E
DNA mismatch repair and DNA polymerase (POLE and
POLD1) proofreading are responsible for genomic stability.
Recent data by Domingo and colleagues [57] demonstrated
that pathogenic POLE proofreading domain mutations occur
in 1% of CRC, in which they are responsible of an
ultramutated status. POLE mutations are correlated with
younger age, male sex, and right-sided tumours, and with a
strong tendency to mutual exclusivity with dMMR. In this
study, POLE-mutant CRCs displayed significantly increased
CD8+ cell infiltrates compared to pMMR tumours and higher
expression of cytotoxic markers and immune checkpoints.
More importantly, POLE-mutant status has been shown to
be a very strong positive prognostic factor in terms of tumour
recurrence and DFS, especially in stage II patients (HR = 0.22,
p = 0.014 in CRC recurrence). This strong signal needs to be
validated in prospective clinical trials.
3.7 SMAD4
The SMAD4 tumour-suppressor gene (TSG) codes for a com-
mon intracellular mediator of the TGFb superfamily signalling
pathway: it is involved in the regulation of cell proliferation,
differentiation, apoptosis, and cell migration, and it is one of
the most commonly altered pathways in human cancers.
Analysis of the PETACC-3 trial [16] indicated loss of
SMAD4 expression, found in 21% of patients, as a biomarker
of poor prognosis in terms of RFS (HR = 1.47, 95% CI = 1.19
to 1.81, P < 0.001) and OS (HR = 1.58, 95%CI = 1.23 to 2.01,
P < 0.001) both in stage II and stage III CC. Moreover,
SMAD4 loss was statistically significantly more frequently
in stage III than in stage II (23% vs 18%, p = 0.03).
Nevertheless, the impact of SMAD4 loss (73/293 cases) was
not statistically significant in terms of RFS or in OS for pa-
tients in stage II CC in a more recent study [28].
3.8 CIMP
The transcriptional inactivation of tumour suppressor genes
by promoter hypermethylation is an epigenetic phenomenon
involved in carcinogenesis of CC. The CpG island methylator
phenotype is one of the most recently recognized mechanisms
of colorectal carcinogenesis [58]. The CIMP phenotype is due
to CpG island methylation in the promoter regions of certain
tumour suppressor genes involved in malignant transforma-
tion. The contradictory results published regarding the role of
CIMP as a prognostic biomarker could be due to an overlap
between the CIMP+ phenotype and the MSI phenotype, asso-
ciated in 50% of cases with BRAF mutation. The most com-
mon molecular and clinical features of CIMP+ colon cancer
are female sex, older age, proximal tumour location, BRAF
mutation, wild-type KRAS and TP53 genes, and MSI [59].
Targ Oncol (2017) 12:265–275 269
In two different studies in stage III CRC, CIMP+ has been
associated with shorter OS for those patients treated with sur-
gery alone as compared to CIMP− patients [60] and the
CIMP+ subgroup with BRAF mutation and proximal tumour
location had a significantly worse DFS [61]. Five other studies
have investigated the prognostic value of CIMP+ in mixed
stage II and III CRC: three studies showed a decrease in
DFS in the CIMP+ group [62–64], although no significant
difference in DFS between CIMP+ and CIMP− was noticed
in the other two [65, 66]. Finally, Donada et al. [67] have
studied the prognostic impact of CIMP in stage II CRC and
found a benefit of adjuvant 5-FU in terms of OS in CIMP+
patients.
In conclusion, the prognostic impact of the CIMP+ pheno-
type remains very controversial, since many factors, especial-
ly BRAFmutation andMSI status, could influence the results.
Moreover, the lack of standardization and consensus for the
definition of CIMP status introduces another important bias.
Although it appears that CIMP+ phenotype is associated with
decreased OS and DFS in MSS patients, it warrants further
investigations.
4 Immune Contexture
The complex interplay between the immune system and can-
cer has been a matter of research for decades, but only recently
a deeper knowledge in this field has led to the development of
effective immunotherapy as a novel treatment option for dif-
ferent types of cancer [68]. The recognition of the dual role
that the immune system has in regards to cancer development
led to the three BEs^ of the cancer immunoediting theory —
Elimination, Equilibrium, and Escape [69].
The immune contexture consists of type of immune cells,
their location, density, and functional orientation and can in-
fluence tumour invasion, recurrence, and metastasis [70].
In CC, mounting evidence indicates immune infiltration as
a crucial prognostic factor. Beginning in 2006, Galon and
colleagues demonstrated the immune-contexture as a positive
and independent prognostic factor [71–78] for early stage CC,
with a stronger discriminatory power of standard TNM. For
this reason, the authors developed the Immunoscore® (IM): a
prognostic tool based on numbers of lymphocyte populations
(CD3/CD45RO) in the tumour core and invasive margins.
Recently, a Society for Immunotherapy of Cancer-led interna-
tional consortium of 23 pathology expert centres from 17
countries validated the Immunoscore® in 1336 patients with
stage I/II/III CC [29]. In the training set TTR was shorter
among 332 patients (48.1%) with Low-IM (0 or 1 IM) CC
vs. 358 patients with High-IM CC (HR = 0.35; 0.23–0.52;
P < 0.0001). In the internal validation set with 630 patients,
TTR was also shorter among 303 patients with Low-IM CC
vs. 327 patients with High-IM CC (HR = 0.54; 0.34–0.84;
P = 0.006). In both groups, results were independent of age,
sex, tumour stage, and sidedness. Among patients with stage II
CC, the difference in TTR between Low and High-IM was
significant both in the training set (HR = 0.27; P < 0.0001) and
in the internal validation set (HR = 0.46; P = 0.014). We may
conclude that Low-IM identified a subgroup of patients with
high-risk stage II CC, but such a potentially important prognostic
factor must be validated in a prospective cohort of patients in
order to establish its impact in daily clinical practice. Moreover,
since it may predict the efficacy of immunotherapies as adjuvant
treatment, its use could become extremely important in the near
future.
5 Sidedness
An increasingly large amount of evidence is accumulating
showing that colon tumours proximal and distal to splenic
flexure are distinct clinical and biological entities. A recent
meta-analysis included 66 studies with about 1.5 million pa-
tients with a median follow-up of 65 months [79]. Left-sided
primary tumour location was associated with a significantly
reduced risk of death (HR = 0.82; 0.79–0.84; P < 0.001) in all
stages. Studies that included only patients with stage IV dis-
ease (n = 20) compared with those that included patients with
stages I to III only (n = 25) showed a significantly greater
effect on mortality for patients with left CC (HR = 0.73,
0.69–0.78 vs HR = 0.84, 0.79–0.89; P < .001 for subgroups
difference). Although this meta-analysis has some limitations,
such as a notable heterogeneity of included studies, it confirms
the important role of sidedness in CC, both in metastatic and
adjuvant settings. The biological, embryological, and genetic
differences between right and left CC have to be taken into
account as a stratification factor for future studies to establish
the efficacy of drugs and patients’ prognosis [80].
6 Consensus Molecular Classification
Cancer genomes can now be systemically studied in their en-
tirety within a single day, opening new incredible opportunities
to analyse and find patient-specific cancer mutations, eventual-
ly responsible for tumour progression. Therefore, individual
cancer sequencingmay provide the basis of personalized cancer
management. Some studies tried to classify different types of
CC based on gene expression [81–86] to identify subgroups of
patients with distinct prognosis and to improve the current dis-
ease stratification based on clinico-pathological variables.
Because of the extreme variability of all these classifications,
Guinney and colleagues [87] formed an international consor-
tium and identified four ConsensusMolecular Subtypes (CMS)
with distinctive characteristics: CMS1 (14%) are hypermutated,
MSI, and exhibit increased expression of genes associated with
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a diffuse immune infiltrate, mainly composed of TH1 and cy-
totoxic T cells, along with strong activation of immune evasion
pathways, frequent occurrence of BRAF mutations, females
with right-sided lesions and worse survival after relapse, and
CIMP-H status; CMS2 (37%) are epithelial, and show marked
WNT and MYC signalling activation; CMS3 (13%) are asso-
ciated with mixed MMR status, CIMP and SCNA low, KRAS
mutations, and metabolic deregulation; CMS4 (23%) showed
clear upregulation of both genes implicated in epithelial-to-
mesenchymal transition (EMT) and of signatures associated
with the activation of transforming growth factor (TGF)-β sig-
nalling, angiogenesis, matrix remodelling pathways, and the
complement-mediated inflammatory system, and they had
worse OS and RFS, irrespective of patient cohort; 13% of sam-
ples showed mixed features. The 5-year OS rates were 62% for
CMS4, 74% for CMS1, 75% for CMS3 and 77% for CMS2:
these differences in prognosis with unsupervised gene expres-
sion signatures confirm the clinical relevance of the intrinsic
biological processes implicated in each CMS.
Interesting for this review, the authors separately analysed
prognosis in the subset of patients enrolled in PETACC-3 trial
(stage II and III CC) with similar results in terms of OS, RFS,
and survival after relapse.
On the one hand, the impact of this classification in daily
practice is still low, because it has to be validated before it can
be a useful tool for oncologists. On the other hand, it could be
used in clinical trials to select patients for tailored therapy in
the adjuvant setting.
7 Gene Signatures
Many different gene signatures have been tested in several
retrospective and prospective studies, but none of them is used
in clinical practice as a decision-making tool. Moreover, only
few gene signatures have been validated in external indepen-
dent data sets: OncotypeDX®, GeneFx® Colon, ColoPrint®,
OncoDefender-CRC®, and ColonPRS® are currently avail-
able [88]. Nevertheless, only OncotypeDx® and GeneFx®
Colon have been investigated in co-variable analysis with
MSI status and pT4 on FFPE samples, collected from prospec-
tive, randomized clinical datasets.
OncotypeDx® was first validated in the Quasar trial, in
which it could separate patients with high risk of recurrence
(RR) and low RR (High Recurrence Score, 3- year RR of 22%
and low RS, 3-year RR of 12%) [89], and it remained signif-
icant also in a multivariate analysis with MSI status and pT4.
These results have been further confirmed in two other clinical
trials: CALGB 9581 [90] and NSABP C-07 [91]. In the for-
mer, the prognostic value of RS was most evident in the sub-
group of T3 MSS patients: 5-year RR in the prespecified low
and high RS groups were 13% and 21%, respectively. In the
latter, average 5-year recurrence risk rates (low, intermediate,
and high) were: stage II, 9%, 13% and 18%; stage III 21%,
29%, and 38%. No predictive role has been demonstrated in
all these studies. Finally, in the Sunrise study [92], patients
with stage II disease in the high-risk group had a 5-year risk of
recurrence comparable to patients with stage IIIA to IIIB dis-
ease in the low-risk group (19% vs 20%), whereas patients
with stage IIIA to IIIB disease in the high-risk group had a
recurrence risk similar to that of patients with stage IIIC dis-
ease in the low-risk group (approximately 38%). Therefore,
OncotypeDx® is themost largely and independently validated
gene signature, but its discriminatory power is too weak to be
used in daily clinical practice, and it might have to be integrat-
ed with other determinants.
GeneFx® is a DNA microarray-based gene signature de-
veloped using FFPE tumour samples of 215 stage II CC pa-
tients [93]. The signature could discriminate patients with
higher relapse rate and cancer-related death with a HR of
2.53 (p < 0.001). More recently, it has been significantly as-
sociated with RFI after adjustment for other prognostic factors
(HR = 2.13; 95% CI, 1.3 to 3.5; P < 0.01) in multivariable
analysis [94].
8 Circulating Tumour DNA
Genomic profiles of circulating cell-free tumour DNA
(ctDNA) were shown to match those of the corresponding
tumours, with important implications for both molecular pa-
thology and clinical oncology. Analyses of liquid biopsies can
be used to monitor response to treatment, assess the emer-
gence of drug resistance, and quantify minimal residual dis-
ease (MRD), both in adjuvant and metastatic settings [95].
Indeed, ctDNA levels can be used to monitor MRD after sur-
gery or other curative treatments and liquid biopsies can be
applied to the monitoring of response and/or resistance to
systemic therapy.
The ctDNA is a promising biomarker for the noninvasive
assessment of cancer burden. Recently, a study published in
Science Translational Medicine [96] evaluated the ability of
ctDNA to detect MRD in 1046 plasma samples from a pro-
spective cohort of 230 patients with resected stage II CC. It
showed that ctDNA detection has 48% sensitivity and 100%
specificity in the prediction of radiologic recurrence at
36 months in postoperative patients. Three-year RFS esti-
mates were 0% for the ctDNA-positive group and 90% for
the ctDNA-negative group. However, an additional 16 of
164 patients (9.8%) experienced disease recurrence but were
ctDNA-negative. Furthermore, the authors also noted a higher
specificity for ctDNA testing over CT scans. Patients treated
with chemotherapy who had detection of ctDNA after treat-
ment were associated with a higher risk of recurrence (HR, 11;
95% CI, 1.8–68; P = 0.001). In patients not treated with adju-
vant chemotherapy, 11 out of 14 (79%) patients with ctDNA
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detection postoperatively, had recurred at a median follow-up
of 27 months; recurrence occurred in only 16 (9.8%) of 164
patients with negative ctDNA (HR = 18; P < 0.001). From
these results, authors noted that ctDNA could be a real-time
marker of response to adjuvant chemotherapy, faster and less
invasive than a CT scan, but this must be validated in a larger
cohort of patients. Indeed, detection of ctDNA after resection
of stage II CC may identify patients at the highest risk of
recurrence and help inform adjuvant treatment decisions.
More recently, a systematic review strongly suggested that
patients with ctDNA-positive CRC have an unfavourable
prognosis, both in terms of DFS and OS [97], even if there
are major limitations in this analysis, such as clinical and
methodological heterogeneity of studies included.
The development of novel technologies such as ctDNA is
already implemented and used in clinical practice for patients
with NSCLC and is likely to become an additional tool to
monitor patients with gastrointestinal (GI) cancer in real time
on a molecular level in the future.
9 Conclusion
In the last decades, although mounting evidence has been
shedding light on multiple factors that can influence the prog-
nosis of patients with early CC, no changes in adjuvant treat-
ment have been made based on these biomarkers.
Furthermore, the number of effective treatment options for
patients in the adjuvant setting has not increased, despite
many drug-targetable factors having been discovered.
Unfortunately, none of these drugs showed efficacy in early
CC patients so far. The only standardized and efficacious
treatment is 5-FU + oxaliplatin-based chemotherapy
(oxaliplatin only in stage III). The exact duration of chemo-
therapy (3 vs 6 months) will be addressed by the results com-
ing from the TOSCA trial expected in a few months, which
will have strong impact on our clinical practice. More impor-
tantly, we still cannot recognize which patient really needs
chemotherapy and which patient is already cured by surgery
alone: this exposes the patient to chemotherapy adverse events
without any benefit.
Concerning prognostic factors, the most validated and im-
portant ones for our practice are pT4 and MSI status, since all
other biomarkers need to be further investigated and validated
before they can be used in clinical practice. Accordingly, uni-
versal MMR or MSI testing should be performed for all pa-
tients with early CC: stage IIMSI-H tumours may have a good
prognosis and do not benefit from 5-FU adjuvant therapy. In
addition to this, MSI-H patients could be involved in future
clinical trials with immunotherapy as adjuvant treatment.
Nevertheless, very promising results have been shown for
POLE, SMAD4, CDX2, ErbB2, KRAS, and BRAF as prog-
nostic biomarkers, and especially POLE (immunotherapy),
ErbB2 (targeted therapy), and CDX2 (chemotherapy for
CDX2-neg patient) hold potential as predictive factors.
The immunoscore® may be a new way to classify patient
both as a prognostic and a predictive factor, since it may pre-
dict the benefit from immunotherapy, but it must be validated
in a prospective cohort of patients.
Although the development of next generation sequencing
(NGS) could make molecular classification more and more
available in every cancer center, the CMS is still too compli-
cated to become a real tool useful in daily clinical practice.
Between all gene signatures tested, the most validated is
OncotypeDx®, which can be useful as an integration for other
determinants, but data available so far are not sufficient to
recommend the use of these tools to determine adjuvant
therapy.
A new and very promising technology is ctDNA that may
identify patients with stage II CC at high risk of recurrence of
both post resection and post adjuvant chemotherapy, but larger
studies are needed to confirm this.
In the future, the challenge is to integrate all these promis-
ing biomarkers on how to guide us on which patient benefits
from chemotherapy and which patient needs other types of
treatment (immunotherapy or targeted therapy).
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